A Simple Spectrophotometric Determination of Some Phenothiazine Drugs in Pharmaceutical Samples

Total Page:16

File Type:pdf, Size:1020Kb

A Simple Spectrophotometric Determination of Some Phenothiazine Drugs in Pharmaceutical Samples ANALYTICAL SCIENCES NOVEMBER 2000, VOL. 16 1127 2000 © The Japan Society for Analytical Chemistry A Simple Spectrophotometric Determination of Some Phenothiazine Drugs in Pharmaceutical Samples Padmarajaiah NAGARAJA,* Nandipura D. DINESH,* Netkal M. MADE GOWDA,** and Kanchugarakoppal S. RANGAPPA*† *Department of Chemistry, University of Mysore, Manasagangotri, Mysore 570 006, India **Department of Chemistry, Western Illinois University, Macomb, IL 61455, USA A new, simple and sensitive spectrophotometric method for the determination of some phenothiazine drugs has been developed. The proposed method is based on the reaction of promethazine hydrochloride (PH), chlorpromazine hydrochloride (CPH), triflupromazine hydrochloride (TPH), fluphenazine hydrochloride (FPH), trifluoperazine hydrochloride (TFPH), perazine dimaleate (PDM) and prochlorperazine maleate (PCPM) with iron(III) and a subsequent reaction with ferricyanide in an acetic acid medium to yield Prussian blue colored product with a maximum absorption at 700 – 720 nm. The common excipients used as additives in pharmaceuticals do not interfere with the proposed method. Analytical data for determination of the pure compound are presented together with the applications of the proposed method to the analysis of some pharmaceutical formulations. The results compare favorably with those of the official method. (Received July 13, 2000; Accepted September 13, 2000) Phenothiazines are an important group of neuroleptics used in drug on heating for 10 min and have low sensitivity.28 the treatment of moderate and severe mental and emotional However, no method has been found for dealing with the use of conditions. They are also known for their antiemetic effects, the combinations of these two reagents for the spectrophotometric potency of the effects of anaesthetics, analgesics and sedatives determination of phenothiazine derivatives. This method offers and also as antihistamines.1 More than 100 compounds derived the advantages of simplicity, specificity without the need of from the fundamental phenothiazine skeleton have been extraction or heating, besides having higher sensitivity range synthesized and pharmacologically tested in the past four than most of the existing spectrophotometric methods. decades.2 The vast number of phenothiazine derivatives and the Moreover, this method is totally free from the twin continued introduction of these drugs have instigated many disadvantages of critical acid or reagent concentration and workers to explore new methods for their determination. Many instability of the colored species; such disadvantages are typical phenothiazine derivatives and their formulations are official in of most spectrophotometric methods. British Pharmacopoeia3 and Indian Pharmacopoeia.4 The methods used for their determination include spctrofluorometry,5 conductometry,6 fluoroimmunoassay,7 Experimental HPLC,8 GLC,9 adsorptive voltametry10 and chemiluminescence measurements.11 Many spectrophotometric methods have been Apparatus already proposed, but some of them either lack sensitivity or A JASCO Model UVIDEC-610 UV-VIS spectrophotometer specificity12–19 or require long heating times20–23 or involve non- with a 1.0-cm matched cell was used for electronic spectral aqueous media.24,25 Almost all spectrophotometric methods are measurements. based on the formation of colored radical cation, which suffer from two disadvantages: critical acid or oxidant concentration Reagents and instability of colored species ranging from 10 – 30 min. All the reagents used were of AR grade where otherwise not Some other spectrophotometric methods have very narrow mentioned. Deionized water was used to prepare all solutions. limits of detection.25,26 Freshly prepared solutions were always employed. Standard The present communication reports on the investigations for solutions of phenothiazines (1000 µg ml–1) were prepared by the use of iron(III) salts in the presence of ferricyanide as dissolving 100 mg each of phenothiazine salts in distilled water reagent for the spectrophotometric determination of and diluting to the mark in a 100-ml calibrated flask. A phenothiazines listed in Table 1. working standard solution of phenothiazines containing 50 µg Ferricyanide has been used as an oxidizing agent for the ml–1 was prepared by further dilution. A potassium ferricyanide determination of phenothiazines by titrimetry.27 Iron(III) salts solution (0.002 M), ferric chloride solution (0.005 M) and a 1:1 are also used as a reagent for the analysis of chlorpromazine acetic acid solution were prepared in water. hydrochloride in hydrochloric acid medium. It reacts with the Recommended procedure † To whom correspondence should be addressed. Aliquots of standard phenothiazine solutions such as PH (2.5 – 1128 ANALYTICAL SCIENCES NOVEMBER 2000, VOL. 16 Table 1 Phenothiazines studied Sl. Derivative Abbrev. Structure No. studied 1. promethazine PH (hydrochloride) 2. chlorpromazine CPH (hydrochloride) 3. triflupromazine TPH (hydrochloride) Fig. 1 Absorption spectra of PH product (1) with reagent blank, (2) PH taken 5 mg ml–1. 4. fluphenazine FPH (hydrochloride) Results and Discussion The spectrophotometric method for the determination of 5. trifluoperazine TFPH (hydrochloride) phenothiazine derivative is based on the oxidation reaction of the drug with iron(III) and subsequent chelation with ferricyanide to form a Prussian blue colored product.29 The factors affecting the color development, reproducibility, 6. perazine PDM sensitivity and adherence to Beer’s law were investigated with dimaleate PH as the model compound, since the other phenothiazine derivatives behaved similarly to it. Spectral characteristics 7. prochlorperazine PCPM A blue complex is formed when PH was allowed to react with maleate iron(III) salts in the presence of ferricyanide in acetic acid medium with maximum absorption as shown in Fig. 1. The colorless reagent blank has practically negligible absorbance at this wavelength. Optimum conditions for complex formation 175 µg), CPH (5 – 200 µg), TPH (6.25 – 200 µg), FPH (6.25 – In order to establish the optimum conditions necessary for a 200 µg), PDM (5 – 200 µg), PCPM (10 – 200 µg) or TFPH (12.5 rapid and quantitative formation of the colored product with – 200 µg) were transferred into 25 ml calibrated flasks maximum stability and sensitivity, the investigators measured separately, to each flask, 4 ml of ferricyanide and 2 ml of ferric the absorbance of a series of solutions by varying one and fixing chloride were added. Each mixture was set aside for 10 min. the other parameters at 700 nm. After 3.5 ml of 1:1 acetic acid was added, the contents were It was found that a 0.005 M solution of ferric chloride in the diluted to the mark with water and mixed thoroughly; after 20 range 1.0 – 3.0 ml and a 0.002 M solution of potassium min, the absorbance values at λmax 700 – 720 were measured ferricyanide in the range 2.0 – 6.0 ml were necessary to achieve against a reagent blank and a calibration graph was constructed. the maximum color intensity of the product. The color intensity decreased below the lower limit and above the upper limit. Procedure for tablets Therefore, 2.0 ml of ferric chloride and 4.0 ml of ferricyanide Twenty tablets were weighed and finely powdered. An were recommended for all measurements. accurately weighed portion of the powder equivalent to 50 mg Dilution of the blue product with different solvents like water, of the phenothiazine salt was transferred into a 100-ml methanol, ethanol, hydrochloric acid, sulfuric acid, phosphoric calibrated flask and diluted to volume with water. Using a acid and acetic acid were tested. Nitric acid was not used mechanical stirrer, the powder was completely disintegrated and because of its strong oxidizing power. In methanol or ethanol the solution was filtered. A suitable aliquot of this solution in medium, the blue color product precipitates out. Results the individual phenothiazine working range was treated as showed that 1:1 acetic acid gives clear blue color with described in the recommended procedure. maximum intensity and stability compared to hydrochloric, sulfuric or phosphoric acids. It was found that 1:1 solution of Procedure for injections acetic acid in the range of 2.5 – 15.0 ml was necessary to get An accurately measured volume was appropriately diluted to clear, sensitive and stable color. Therefore, a 3.5 ml volume of get 500 µg ml–1 of phenothiazine salt solution. A suitable acetic acid was recommended for all subsequent measurements. aliquot of solution was taken and the recommended procedure was followed for the analysis of drug content. ANALYTICAL SCIENCES NOVEMBER 2000, VOL. 16 1129 Table 2 Parameters for the spectrophotometric determination of phenothiazine derivatives Parameter PH CPH TFPH FPH PDM PCPM TFPH Color blue blue blue blue blue blue blue λmax (nm) 700 700 700 720 720 720 720 Stability (h) 48 48 48 48 48 48 48 Beer’s law range (µg ml–1) 0.1 – 7 0.2 – 8 0.25 – 8 0.25 – 8 0.2 – 8 0.4 – 8 0.5 – 8 Molar absorptivitiy (L mol–1 cm–1) 3.66 × 104 2.14 × 104 2.72× 104 2.87 × 104 2.86 × 104 2.46 × 104 2.43 × 104 Sandell’s sensitivity (µg cm–2) 0.0087 0.0166 0.0176 0.0177 0.0199 0.0246 0.0160 Photometric range (µg ml–1) 0.5 – 6 0.8 – 7.2 1 – 6.5 0.9 – 7 0.8 – 7.0 1 – 6 1.2 – 6.4 Regression equation (ya) Slope (a) 0.026 0.020 0.111 0.039 0.110 0.020 0.038 Intercept (b) 0.010 –0.050 0.037 –0.032 0.037 –0.050 0.011 Correlation coefficient (r) 0.998 0.998 0.997 1.010 0.998 0.998 0.990 R.S.D. (%)b 1.12 1.40 1.22 0.80 1.13 1.14 1.02 a. y = ax + b where x is the concentration (µg ml–1) of phenothiazines. b. Calculated from five determinations. Table 3 Determination of PHa in the presence of excipients seriously. Material Amount/mg % Recovery of PH ± % RSDb Application of the method The applicability of the method for the assay of Lactose 40 98.9 ± 1.41 Dextrose 40 98.6 ± 1.10 pharmaceutical formulations was examined.
Recommended publications
  • Adverse Reactions to Hallucinogenic Drugs. 1Rnstttutton National Test
    DOCUMENT RESUME ED 034 696 SE 007 743 AUTROP Meyer, Roger E. , Fd. TITLE Adverse Reactions to Hallucinogenic Drugs. 1rNSTTTUTTON National Test. of Mental Health (DHEW), Bethesda, Md. PUB DATP Sep 67 NOTE 118p.; Conference held at the National Institute of Mental Health, Chevy Chase, Maryland, September 29, 1967 AVATLABLE FROM Superintendent of Documents, Government Printing Office, Washington, D. C. 20402 ($1.25). FDPS PRICE FDPS Price MFc0.50 HC Not Available from EDRS. DESCPTPTOPS Conference Reports, *Drug Abuse, Health Education, *Lysergic Acid Diethylamide, *Medical Research, *Mental Health IDENTIFIEPS Hallucinogenic Drugs ABSTPACT This reports a conference of psychologists, psychiatrists, geneticists and others concerned with the biological and psychological effects of lysergic acid diethylamide and other hallucinogenic drugs. Clinical data are presented on adverse drug reactions. The difficulty of determining the causes of adverse reactions is discussed, as are different methods of therapy. Data are also presented on the psychological and physiolcgical effects of L.S.D. given as a treatment under controlled medical conditions. Possible genetic effects of L.S.D. and other drugs are discussed on the basis of data from laboratory animals and humans. Also discussed are needs for futher research. The necessity to aviod scare techniques in disseminating information about drugs is emphasized. An aprentlix includes seven background papers reprinted from professional journals, and a bibliography of current articles on the possible genetic effects of drugs. (EB) National Clearinghouse for Mental Health Information VA-w. Alb alb !bAm I.S. MOMS Of NAM MON tMAN IONE Of NMI 105 NUNN NU IN WINES UAWAS RCM NIN 01 NUN N ONMININI 01011110 0.
    [Show full text]
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
    [Show full text]
  • Studies with Lysergic Acid Diethylamide in Regressed Schizophrenics
    CHAPTER 15 _ Studies with Lysergic Acid Diethylamide in Regressed Schizophrenics By FREDERICK B. CHARAT AN, M.D. OF THE MANY studies carried out with lysergic acid diethylamide in the last 15 years, relatively few have dealt with regressed schizophrenics. Most workers have used comparatively small doses of LSD. Some gave up to 600 gamma orally. Others reported the effects of up to 500 gamma intra- muscularly, 180 gamma intravenously and 60 gamma intrathecally in small series of cases. Several investigators agreed that in chronic schizophrenics higher doses of LSD than those administered to undeteriorated schizo- phrenics and nonpsychotics have been required to produce psychic effects. Apart from the slight response of chronic schizophrenics to doses of LSD which lead to marked and characteristic effects in other subjects, tolerance to the drug seems to develop in as brief a period as three days. These differences in response to LSD pose some interesting problems. Is the lack of response in chronic schizophrenics merely an apparent one caused by their inability to communicate their inner experiences? Is it due to the development of some immune state connected with biochemical alter- ations produced during the psychosis? Is it the reflection of a metabolic difference between schizophrenics and non-schizophrenics? May it be a general manifestation of schizophrenic underresponsiveness to virtually any stress, once the chronic stagnant phase of the psychosis has been reached? Clear answers to all these questions cannot yet be given. The present investi- gation was undertaken to examine further the responses of chronic schizo- phrenics to large doses of LSD and also to observe the effect of other drugs upon this response.
    [Show full text]
  • Perphenazine-151548-PI.Pdf
    PRESCRIBING INFORMATION PERPHENAZINE Perphenazine Tablets USP 2 mg , 4 mg, 8mg, and 16 mg Antipsychotic/Antiemetic AA Pharma Inc. DATE OF REVISION: April 12, 2012 1165 Creditsone Road, Unit #1 Vaughan, Ontario L4K 4N7 Control Number: 151548 PRESCRIBING INFORMATION PERPHENAZINE Perphenazine Tablets USP 2 mg, 4 mg, 8 mg and 16 mg THERAPEUTIC CLASSIFICATION Antipsychotic/Antiemetic ACTIONS AND CLINICAL PHARMACOLOGY Perphenazine is a piperazine phenothiazine derivative with antipsychotic, antiemetic and weak sedative activity. Perphenazine has actions similar to those of other phenothiazine derivatives but appears to be less sedating and to have a weak propensity for causing hypotension or potentiating the effects of CNS depressants and anesthetics. However, it produces a high incidence of extrapyramidal reactions. Perphenazine is well absorbed from the gastrointestinal tract. Onset of action following oral administration is 30 to 40 minutes. Duration of action is 3 to 4 hours. Perphenazine distributes to most body tissues with high concentrations being distributed into liver and spleen. Perphenazine enters the enterohepatic circulation and is excreted chiefly in the feces. INDICATIONS AND CLINICAL USE Perphenazine is indicated in the management of manifestations of psychotic disorders. It is also effective in controlling nausea and vomiting due to stimulation of the chemoreceptor trigger zone. 1 Perphenazine has not been shown effective for the management of behavioral complications in patients with mental retardation. CONTRAINDICATIONS Should not be administered in the presence of circulatory collapse, altered states of consciousness or comatose states, particularly when these are due to intoxication with central depressant drugs (alcohol, hypnotics, narcotics). It is contraindicated in severely depressed patients, in the presence of blood dyscrasias, liver disease, renal insufficiency, pheochromocytoma, or in patients with severe cardiovascular disorders or a history of hypersensitivity to phenothiazine derivatives.
    [Show full text]
  • Preparation of Metabolites by Chemical Reaction: Conversion of Antipsychotic Phenothiazines to Their Sulfoxides and Tertiary
    396 Journal of Health Science, 50(4) 396–406 (2004) Preparation of Metabolites N-oxides from parent drug could be confirmed when the collisional energy was decreased to 10 eV. 1H- and by Chemical Reaction: 13C-NMR spectral data confirmed the structure of the Conversion of Antipsychotic prepared mianserin N-oxide to be 2-oxide. In conclu- sion, a simple and rapid preparation method for oxide Phenothiazines to their metabolites of phenothiazines and tertiary amino cy- Sulfoxides and Tertiary clic antidepressants available as analytical standards was established. Amino Cyclic Key words —–— metabolite, chemical preparation, ox- Antidepressants ide, phenothiazine, cyclic antidepressants, mass spectros- to their N-Oxide with copy Hydrogen Peroxide Using Titanosilicate INTRODUCTION Catalyst The identification and quantification of drugs Akira Ogamo* and Mariko Fukumoto ingested into human bodies require comprehensive information covering the target drugs themselves and School of Pharmaceutical Sciences, Kitasato University, their metabolites. To carry out a quantitative analy- Shirokane 5–9–1, Minato-ku, Tokyo 108–8641, Japan sis, the standard substances of metabolites are es- (Received March 5, 2004; Accepted April 11, 2004) sential. Some important metabolites can be obtained as commercial products, but many metabolites, es- The aim of this study was to establish a prepara- pecially those of new drugs, are difficult to obtain tion method needed to analyze the metabolites of an as standard samples. These problems have been analytical procedure for antipsychotic phenothiazines solved by using experimental animals or isolated and tertiary amino cyclic antidepressants by chemical enzyme systems originating from biological mate- reaction. These drugs were oxidized to their sulfoxide rials.
    [Show full text]
  • Phenothiazine Poisoning a Review of 48 Cases
    Refer to: Barry D, Meyskens FL Jr, Becker CE: Phenothiazine poison- ing-A review of 48 cases. Calif Med 118:1-5, Jan 1973 California Medicine THE WESTERN JOURNAL OF MEDICINE Phenothiazine Poisoning A Review of 48 Cases DANIEL BARRY, B.A., FRANK L. MEYSKENS, JR., M.D., AND CHARLES E. BECKER, M.D., San Francisco * Of 48 cases of phenothiazine poisoning that were analyzed, 34 were attributed to stuicide attempts, nine to accidental ingestion, and five to drug reactions. As outpatient treatment of schizophrenia increases, cases of over- dose with phenothiazine drugs may be expected to increase also. The prescribing of multiple phenothiazines and antidepressants is probably contributory to the occurrence of mixed drug ingestions. The symptoms and signs of phenothiazine poisoning are largely predictable if the atropine-like, alpha-blocking, quinidine-like, and extrapyramidal actions of phenothiazines are appreciated, Unexplain- able tachypnea and paradoxical miosis were noted in severe cases. In one case in the study phenothiazine intoxication was present in the newborn infant of a schizophrenic mother. PHENOTHIAZINES ARE BECOMING household drugs tionable advertising campaigns advocating phe- in Califomnia. The closing of state hospitals with nothiazines for the treatment of a wide variety the concomitant institution of mass outpatient of ailments have made these drugs generally treatment of chronic schizophrenics through com- available. The high incidence of schizophrenia munity mental health centers, and recent quesv in young adulthood and the increasing suicide From the Detoxification Unit, San Francisco General Hospital, and rate in this age group" suggest that phenothia- the Department of Clinical Pharmacology, University of California, San Francisco.
    [Show full text]
  • Neuroleptic Malignant Syndrome in a Patient
    Psychiatria Danubina, 2018; Vol. 30, Suppl. 7, pp 415-417 Conference paper © Medicinska naklada - Zagreb, Croatia NEUROLEPTIC MALIGNANT SYNDROME IN A PATIENT TREATED WITH CLOTIAPINE Clémentine Lantin, Miriam Franco, François-Xavier Dekeuleneer, Didier Chamart & Juan Martin Tecco Mental Health Unit, Centre Hospitalier Universitaire et Psychiatrique de Mons-Borinage (CHUP-MB), Mons, Belgium SUMMARY Background: Neuroleptic malignant syndrome (NMS), which is linked to the use of antipsychotic medication, is a potentially lethal neurological emergency. The interest of our study is that NMS induced by the use of clotiapine has never previously been described. Subjects and methods: We present the case of a 61-year old man whose sleep disorders were treated with clotiapine 40 mg/day. After 7 days of taking 40 mg clotiapine, the patient presented with a deterioration of his general health which had gradually taken hold, with altered consciousness accompanied by generalised muscle rigidity and hypersalivation. Laboratory blood tests revealed elevated levels of Creatine Phosphokinase (CPK) at 812 U/l. The patient was diagnosed with NMS and treated accordingly. Results: The mechanism that underlies the appearance of NMS remains largely unknown. Clotiapine is a second-generation antipsychotic, first released onto the market in the 1970s, and is available in a few countries, including Belgium. NMS is treated as a medical emergency due to the possibility of morbidity and death. The first step in the treatment of NMS consists in withholding the agent suspected of provoking the symptoms. Conclusions: NMS is difficult to diagnose due to a great variability in clinical presentations and the absence of specific tests and laboratory results.
    [Show full text]
  • Trilafon Tablets & Trilafon Injection Final Printed Labeling
    PAGE 1 TRILAFON TABLETS & TRILAFON INJECTION FINAL PRINTED LABELING 1 TRILAFON Ò 2 brand of perphenazine, USP 3 Tablets, 4 Injection 5 6 DESCRIPTION TRILAFON products contain perphenazine, USP (4-[3-(2- 7 chlorophenothiazin-10-yl)propyl]-1-piper-azineethanol), a piperazinyl phenothiazine 8 having the chemical formula, C21H26CIN3OS. They are available as Tablets, 2, 4, 9 8, and 16 mg; and Injection, perphenazine 5 mg per 1 mL. 10 The inactive ingredients for TRILAFON Tablets, 2, 4, 8, and 16 mg, include: 11 acacia, black iron oxide, butylparaben, calcium phosphate, calcium sulfate, 12 carnauba wax, corn starch, lactose, magnesium stearate, sugar, titanium dioxide, 13 and white wax. The inactive ingredients for TRILAFON Injection include: citric 14 acid, sodium bisulfite, sodium hydroxide, and water. 15 ACTIONS Perphenazine has actions at all levels of the central nervous system, 16 particularly the hypothalamus. However, the site and mechanism of action of 17 therapeutic effect are not known. 18 CLINICAL PHARMACOLOGY Pharmacokinetics: Following oral administration 19 of TRILAFON® Tablets, mean peak plasma perphenazine concentrations were 20 observed between 1 to 3 hours. The plasma elimination half-life of perphenazine 21 was independent of dose and ranged between 9 and 12 hours. In a study in which 22 normal volunteers (n=12) received TRILAFON 4 mg q8h for 5 days, steady-state 23 concentrations of perphenazine were reached within 72 hours. Mean (%CV) Cmax 24 and Cmin values for perphenazine and 7-hydroxyperphenazine at steady-state are 25 listed below: 26 ParameterPerphenazine 7-Hydroxyperphenazine 27 Cmax (pg/mL) 984 (43) 509 (25) 28 Cmin (pg/mL) 442 (76) 350 (56) 1 PAGE 2 TRILAFON TABLETS & TRILAFON INJECTION FINAL PRINTED LABELING 29 Peak 7-hydroxyperphenazine concentrations were observed between 2 to 4 hours 30 with a terminal phase half-life ranging between 9.9 to 18.8 hours.
    [Show full text]
  • Psychotropic Medication Audit Criteria and Guidelines
    Psychotropic Medication Audit Criteria and Guidelines Fluphenazine decanoate (Prolixin®, decanoate) and Haloperidol decanoate (Haldol®, decanoate) PEFC Approved: July 2021 Indications Label: ● Patients with schizophrenia who require prolonged parenteral antipsychotic therapy Off label: • Schizoaffective disorder Black Box Warning ● Increased mortality in elderly patients with dementia-related psychosis Contraindications ● Severe central nervous system depression or comatose states from any cause ● Hypersensitivity to the drug or derivatives ● Haloperidol decanoate Parkinson’s disease Dementia with Lewy bodies ● Fluphenazine decanoate Suspected or established subcortical brain damage Receiving large doses of hypnotics Blood dyscrasias Hepatic disease Warnings and Precautions ● Severe cardiovascular disorders ● Concomitant use with other CNS depressants ● Diagnosis of a seizure disorder or history of seizures ● Haloperidol only 1 Texas Health and Human Services ● hhs.texas.gov Antipsychotics-decanoates Must not be administered intravenously. QTc prolonging conditions (electrolyte imbalances, drugs known to prolong QTc, underlying cardiac abnormalities, hypothyroidism, familial long QT-syndrome) Leukopenia/neutropenia Thyrotoxicosis Myasthenia gravis Bipolar disorder ● Fluphenazine only History of cholestatic jaundice, dermatoses, or other allergic reactions to phenothiazine derivatives Reduced amounts of anesthetics or CNS depressants may be necessary Effects of atropine may be potentiated Use caution in patients exposed
    [Show full text]
  • Piportil Depot 50 Mg/Ml
    Summary of Product Characteristics 1. NAME OF THE MEDICINAL PRODUCT Piportil Depot 50 mg/ml. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Pipotiazine palmitate 50 mg/ml. For full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Depot injection. 4. CLINICAL PARTICULARS 4.1 Therapeutic Indications For the maintenance treatment of schizophrenia and paranoid psychoses and prevention of relapse, especially where compliance with oral medication is a problem 4.2 Posology and method of administration Patients should be stabilised on Piportil Depot under psychiatric supervision. Administration should be by deep intramuscular injection into the gluteal region. Wide variation of response can be expected. The following dosage recommendations are suitable for either indication. Adults: Initially 25mg should be given to assess the response of the patient to the drug. Further doses should be administered at appropriate intervals, increasing by increments of 25 or 50 mg until a satisfactory response is obtained. In clinical practice, Piportil Depot has been shown to have a long duration of action, allowing intervals of 4 weeks between injections for maintenance therapy. Dosage should be adjusted under close supervision to suit each individual patient in order to obtain the best therapeutic response compatible with tolerance. The duration of action depends on the dose administered, allowing dosage intervals to be varied to suit individual circumstances. Most patients respond favourably to a dose of 50-100 mg every 4 weeks, the maximum recommended dose is 200 mg every four weeks. Elderly : Neuroleptics should be used cautiously in the elderly: A reduced starting dose is recommended, ie 5-10 mg might be considered.
    [Show full text]
  • DOMASYS Standard
    New Zealand Data Sheet 04 December 2018 Neulactil-periciazine DATA SHEET 1 NEULACTIL TABLETS Neulactil 2.5 mg tablets Neulactil 10 mg tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Periciazine 2.5mg Periciazine 10mg Excipients with known effect: lactose monohydrate and wheat starch For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Neulactil tablets 2.5 mg: yellow, scored, marked NEULACTIL 10 mg: yellow, scored, marked 10 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Periciazine is indicated: 1. In adults with schizophrenia or other psychoses, for the treatment of symptoms or prevention of relapse. 2. In anxiety, psychomotor agitation, violent or dangerously impulsive behaviour. periciazine is used as an adjunct to the short-term management of these conditions. Periciazine tablets are not recommended for children (see Section 4.3 and 4.4). neulactil-ccsiv4-dsv11-04dec18 Page 1 New Zealand Data Sheet 04 December 2018 Neulactil-periciazine 4.2 DOSE AND METHOD OF ADMINISTRATION Dosage requirements vary with the individual and the severity of the condition being treated. Initial dosage should be low with progressive increases until the desired response is obtained, after which dosage should be adjusted to maintain control of symptoms. Severe conditions (Indication 1) Adults Initially 75 mg per day in divided doses. Dosage should be increased by 25 mg per day at weekly intervals until optimum effect is achieved. Maintenance therapy would not normally be expected to exceed 300mg per day. Elderly Initially 15-30 mg per day in divided doses. If this is well tolerated the dosage may be increased if necessary for optimum control of behaviour.
    [Show full text]
  • Studies on Screening Test for Lysergic Acid Diethylamide by Test Paper
    No. 6] Proc. Japan Acad., 46 (1970) 583 136. Studies on Screening Test for Lysergic Acid Diethylamide by Test Paper By Tetsukichi NIwAGudHTand Takako INOUE National Research Institute of Police Science, Tokyo (Comm.by TanemotoFURUHATA. M.J. A.,June 12, 1970) Various analytical methods for lysergic acid diethylamide (LSD) have been reported and some of them are based on a specific colora- tion of LSD by p-dimethylaminobenzaldehyde. Look has suggested a method for field screening test of LSD using this reagent.i~ It is purpose of this paper to establish a method for screening of LSD by test paper. Experimental. Material. The samples used in this experiment are as follows. LSD, seven kinds of antifebrics and analgesics, eighteen kinds of hypnotics, sixteen kinds of tranquilizers, two kinds of antihistaminics, seven kinds of local anaesthetics, twenty-nine kinds of other drugs, twenty-six kinds of alkaloids and narcotics, and eight kinds of amino acids. Forms of LSD and drugs used are as follows. LSD: pure powder, tablet containing 50 p g of LSD (90% of lactose, 7 % of starch and 3% of talc are mixed, ethanol solution containing 50 pg of LSD is added, the solvent is evaporated and tablet with 8 mm in diameter and 2 mm in thickness is prepared), and sugar cube con- taining 40 pg of LSD (6.3 g of sugar cube is soaked in ethanol solu- tion containing 40 pg of LSD and air-dried). Drugs : pure powder. Reagent. 1. Preparation of test paper. Filter paper (Toyo Roshi No. 131) is soaked in a solution of 2 % p-dimethylamino- benzaldehyde in ethanol, dried in air and cut into strips for test paper.
    [Show full text]